Is Zoetis Inc. overvalued?

In our latest published analysis dated 2026-10-22, ZTS looks meaningfully undervalued. The price recorded at analysis is 79,6 USD versus our fair value of 95,5 USD; the high endpoint is presented separately as potential value of 131 USD. That implies roughly 19.9% upside to fair value at that date.

What is ZTS's fair value?

Our latest published report, analyzed 2026-10-22, gives ZTS a fair value of 95,5 USD and a potential value of 131 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Zoetis Inc.'s archetype; it is a dated research output, not a live price.

Should I buy ZTS now?

Our latest published rating for ZTS, analyzed 2026-10-22, is Buy. Zoetis Inc. looks meaningfully undervalued at the analysis-date price of 79,6 USD versus fair value of 95,5 USD; potential value is 131 USD. This is research for educational purposes, not personalized investment advice.

What are the biggest risks for ZTS?

The dedicated bear-case section in our report analyzed 2026-10-22 documents Zoetis Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.

What is ZTS's rating?

Our latest published rating for ZTS, analyzed 2026-10-22, is Buy, with a published moat assessment of 8.5/10 (Narrow). It reflects our fair value of 95,5 USD, the potential value of 131 USD, and the price recorded at analysis (79,6 USD).

What archetype is ZTS?

In the latest published report analyzed 2026-10-22, Zoetis Inc. is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ZTS.

ZTS stock analysis | StockMarketAgent.AI

StockMarketAgent researchAnalysiert 2026-10-22

Zoetis Inc.

ZTS

Kaufen

19,9 % Kurspotenzial bis zum fairen Wert

Report-date price

79,62 $

Recorded 2026-10-21

Fair Value

95,48 $

Potenzieller Wert

131,22 $

Oberer Bewertungsendpunkt

Wirtschaftlicher Burggraben

Narrow8.5 / 10

Englische QuelleDE

Englische Quelle wird angezeigt, während wir übersetzen

Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.

§1 ZusammenfassungEN

30-Sekunden-AntwortBuy

Preis im Verhältnis zum Wert

Kurs: $79.62
Fairer Wert: $95.48
Potenzialwert: $131.22
Stand: 2026-10-21

Warum es funktionieren kann

Accelerated international expansion of novel monoclonal antibody pain therapies (Lenivia and Portela) combined with a rich late-stage pipeline of multiple potential blockbuster therapies across kidney disease, oncology, and cardiology.

Was unsere Einschätzung ändern würde

Operating margin drops below 34.5% of revenue over a trailing 12-month period.

Zoetis is rated Buy with Fair value of $95.48, offering 19.9% upside from $79.62 (as of 2026-10-21) as market sentiment overreacts to temporary U.S. dermatology competition and clinic visit declines.

The recent sell-off in Zoetis shares followed management's revision of full-year 2026 guidance to revenue of $9.12B to $9.32B (organic contraction of 1% to 3%) and adjusted diluted EPS of $6.15 to $6.25. This reset reflects an 11% decline in Q2 U.S. companion animal sales resulting from lower vet visits and pet owner price sensitivity, alongside targeted gross-to-net discounting to defend dermatology market share.

§2 BärenszenarioEN

In a compounding downside event, U.S. veterinary clinic visits remain depressed while competitive alternatives in dermatology capture significant market share against Apoquel and Cytopoint. Management responds with defensive gross-to-net pricing concessions, causing corporate operating margins to compress from 37.84% in FY2025 to 34.5%. Concurrently, U.S. companion animal volume declines persist across FY2027, restricting 5-year top-line growth to 1.5% and reducing annual operating cash flow generation below $2.4B. Under these conditions, multiple expansion fails to materialize and valuation approaches the lower boundary of the fair value range at $71.42.

Bear scenario

Bear

Probability

25%

Return

-10.3%

Path target

$71.42

Revenue compound growth remains constrained by companion animal clinic softness
Operating margin permanently suppressed at 34.5% due to dermatology rebates
Reduced free cash flow curbs share buyback capacity
Persistent softness in U.S. companion animal clinic visits

In the Bear scenario, competitive entrants capture meaningful market share in canine dermatology, forcing permanent gross-to-net rebates that depress operating margins. U.S. veterinary clinic visits remain sluggish, dampening companion animal demand through FY2028 and constraining earnings compound growth.

Wie diese These scheitern kann

Severe Dermatology Inroads and Permanent Gross-to-Net Degradation

Management acknowledged new competitive entry in U.S. dermatology in Q2 2026 putting volume and market share under pressure and requiring gross-to-net discounting, while revised full-year adjusted net income guidance was cut to a 5% to 9% decline. If competitive entrants capture substantial share in Apoquel and Cytopoint, operating margin drops 300 bps below FY2025 reported levels of 37.84%.^3,5

FV impact

-1.5%

Operating margin 3 points lower throughout

Frühwarnsignale zur Überwachung

Die fünf Entwicklungen, die unsere Anlagethese schwächen würden.

U.S. Companion Animal Organic Revenue Growth

Indicates structural volume erosion and clinic visit decline rather than transitory destocking, impairing core companion animal revenue recovery.

Aktuell:-11% in Q2 2026

Alarm, wennSustained organic contraction worse than -5% through FY2027

§3 WettbewerbsgrabenEN

Narrow

Zoetis possesses a Narrow economic moat anchored by its comprehensive animal health product portfolio, global commercial distribution reach, and deep clinical integration with veterinary practitioners. Animal health therapeutics differ structurally from human pharmaceuticals due to lower patent cliff exposure, smaller brand erosion upon generic entry, and cash-pay consumer dynamics that reward strong brand loyalty and practitioner trust.

The company's commercial scale is unmatched in animal health, generating $9,467M in FY2025 revenue split between U.S. ($5,097M) and International ($4,254M). Although its largest veterinary distributor accounted for approximately 16% of FY2025 revenue, the ultimate purchasing decision rests with thousands of independent clinics and producers who rely on Zoetis technical specialists and point-of-care diagnostic instrumentation.

While competitive entry in dermatology from newer entrants has intensified, requiring targeted gross-to-net pricing investments, the breadth of Zoetis' portfolio across companion animal parasiticides, vaccines, diagnostics, and livestock provides stability that insulates overall corporate returns above capital costs.

Ökonomischer Gewinn

Zoetis generated $3,597M in operating income and $2,283M in free cash flow on $9,467M of revenue in FY2025. With a computed WACC of 7.76% and cost of equity of 8.67%, the company produces economic profits substantially in excess of its capital costs.^2,3,6,7

8.5/ 10

Narrow

Sources of advantage

Direct Global Commercial Infrastructure and Distribution ScaleZoetis deploys the industry's largest dedicated animal health technical sales and diagnostics support network, serving veterinarians across more than 100 countries. In FY2025, U.S. operations generated $5,097M and International generated $4,254M, creating commercial scale that independent biotechnology developers cannot easily replicate.Wide
Proprietary Biologics and Monoclonal Antibody Manufacturing MoatZoetis has pioneered category-defining biologic platforms, including Cytopoint for dermatology and Librela/Solensia for osteoarthritis pain, followed by next-generation monoclonal antibodies Lenivia and Portela recently launched in Europe and Canada. Manufacturing complex biologics at global commercial scale creates substantial intellectual property and regulatory barriers.Wide

Bekannte Bedrohungen für den Wettbewerbsvorteil
Bedrohung	Schweregrad	Zeitrahmen	Minderung
Competitive entry in U.S. canine dermatology targeting Apoquel and Cytopoint market share.	high	Next 12-24 months	Deploying targeted gross-to-net pricing adjustments, leveraging bundled portfolio contracts, and advancing next-generation pipeline assets.⁵

§5 Sensitivität

Abzinsungssatz

Terminalwachstum

	2.0%	2.3%	2.5%	2.8%	3.0%
7.7%	$103.97	$106.81	$109.96	$113.50	$117.48
8.2%	$97.25	$99.54	$102.05	$104.83	$107.92
8.7%	$91.56	$93.43	$95.48	$97.71	$100.17
9.2%	$86.66	$88.22	$89.91	$91.74	$93.75
9.7%	$82.39	$83.71	$85.12	$86.65	$88.30

Zeilen: Abzinsungssatz (Ke für Ertragsmodelle; WACC für Cashflow). Spalten: Terminalwachstum.

Fairer Wert

Änderung der Dauer (Jahre)

	-5	-2	0	+2	+5
Fairer Wert	93,08 $	94,30 $	95,48 $	96,61 $	98,24 $

Dauer des Wettbewerbsvorteils: 5 Jahre im markierten Basisfall. Andere Annahmen bleiben gleich.

Sensitivity reference

The highlighted cell is Fair value when every assumption sits at its base level ($95.48). Each row and column shows what Fair value becomes when one assumption moves.

FCF-Klippe

Free cash flow to the firm stays positive in the first projected year at $2.3B after modeled reinvestment of $409.0M, with terminal value at 81.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.

§7 Entscheidungsbaum für ErgebnisseEN

Übertroffen

Maintain Buy; Maintain core position sizing and verify whether dermatology gross-to-net pressure is abating.

Auslöser: Quarterly adjusted diluted EPS exceeding $1.35 and FY2026 revenue tracking toward the top of guidance at $9.32B.⁵

Demonstrates that international growth and operational cost controls are successfully neutralizing domestic dermatology competition and clinic visit declines.

Im Plan

Maintain Buy; Maintain scheduled tranche deployment and monitor 2027 initial budget commentary.

Auslöser: FY2026 adjusted diluted EPS within $6.15 to $6.25 and revenue within $9.12B to $9.32B.⁵

Confirms that management's revised 2026 outlook is realistic and that earnings power remains on track for recovery toward $6.52 per share in FY2027.

Verfehlt

Downgrade the rating; Halt incremental accumulation and conduct immediate thesis re-assessment regarding moat durability.

Auslöser: FY2026 adjusted diluted EPS below $6.15 and full-year revenue falling below $9.12B.⁵

Signals that competitor inroads in dermatology are accelerating and clinic traffic is deteriorating further, threatening operating margin support at 34.5%.

Ergebnisqualität

Zoetis exhibits high earnings quality supported by strong cash conversion. In FY2025, operating cash flow reached $2,904M and free cash flow was $2,283M, representing an 85.4% conversion rate from reported net income of $2,673M. Stock-based compensation of $83M represents less than 1% of revenue. Non-GAAP adjustments primarily relate to purchase accounting amortization ($90M in FY2026) and discrete restructuring programs ($150M).^6,7

Dynamik der Schätzungen

Following the Q2 2026 earnings release, consensus estimates experienced downward revisions. FY2026 consensus EPS fell from $6.87 pre-event to $6.21, while FY2026 revenue consensus adjusted from $9.74B to $9.25B. FY2027 consensus EPS adjusted from $7.39 to $6.52, reflecting the reset in dermatology pricing assumptions and clinic traffic expectations.¹

Wichtige Kennzahlen vor dem Bericht

Kennzahl:
U.S. Companion Animal Organic Revenue Trend
Aktuell-11% reported in Q2 2026
Warum es wichtig ist
Determines whether pet owner price elasticity and veterinary visit contraction are stabilizing.
Kennzahl:
Dermatology Volume Share and Net Realized Pricing
AktuellDefended via gross-to-net discounting under multi-year contracts
Warum es wichtig ist
Crucial to verify whether Apoquel and Cytopoint retain market leadership against new entrants.

§8 Finanzielle Historie

Gewinn- und Verlustrechnung — letzte sechs Perioden
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$7.78B	$8.08B	$8.54B	$9.26B	$9.47B	+5.0%
Gross profit	$5.31B	$5.48B	$5.83B	$6.40B	$6.67B	+5.9%
Operating income	$2.72B	$2.89B	$3.19B	$3.38B	$3.58B	+7.1%
Net income	$2.04B	$2.11B	$2.34B	$2.49B	$2.67B	+7.0%
EPS (diluted)	$4.27	$4.49	$5.07	$5.47	$6.02	+9.0%
EBITDA	$3.17B	$3.36B	$3.69B	$3.87B	$4.07B	+6.4%
R&D	$508.0M	$539.0M	$614.0M	$686.0M	$698.0M	+8.3%
SG&A	$2.00B	$2.01B	$2.15B	$2.32B	$2.38B	+4.4%

Akzeptierte Jahresprognose
Kennzahl	2026	2027	2028	2029	2030
Revenue	$9.25B	$9.49B

Cashflow

Cash generation is exceptionally strong. In FY2025, cash from operations was $2,904M and capex was $621M, yielding free cash flow of $2,283M. Free cash flow conversion stood at 85.4% of reported net income ($2,673M). For FY2026, forecast FCFF of $2,318M remains resilient despite lower revenue, supported by moderate working capital requirements and stable operating tax rates of 20.36%.^2,6,7

Kapitalallokation

Zoetis demonstrates disciplined capital allocation focused on organic R&D, capacity investment, and aggressive cash return. In FY2025, was $621M (6.6% of ), supporting next-generation biologics capacity. Capital returns prioritize share repurchases, which reduced diluted to 413.2M by October 2026 from 443.8M diluted average shares in FY2025. Total debt stood at $9,493M as of year-end FY2025, representing a manageable debt-to-capital weight of 21.95%. The board declared a $0.53/share dividend in Q4 2026, maintaining an annualized $2.12 payout.

ROIC

Zoetis generates returns on invested capital well above its cost of capital. With an operating margin of 37.84% in FY2025, a modest reinvestment rate of 15%, and an effective tax rate of 20.36%, economic returns remain stable and insulated from competitive shocks.

ROIC exceeds WACC of 7.76% by over 1,000 basis points.

Operating margins lead the healthcare industry by more than 800 basis points.

FY2025 operating income reached $3,597M on $9,467M revenue (37.84% margin), compared to industry average operating margin of 29.5%.

Jüngster Umsatz9,5 Mrd. $Umsatz-CAGR +7,6 %

Betriebsmarge38,0 %10 Geschäftsjahresperioden

Jüngster freier Cashflow2,3 Mrd. $FY2025

Nettoverschuldung7,2 Mrd. $FY2025

Aufschlüsselung der Gewinn- und VerlustrechnungWie sich die Unternehmensgröße in ausgewiesenen Gewinn übersetzt.30. Juni 2026

StockMarketAgent.AI

Finanzhistorische Daten
Umsatz	2.468.000.000 $
Umsatzkosten	673.000.000 $
Bruttogewinn	1.795.000.000 $
Betriebliche Aufwendungen	858.000.000 $
Betriebsergebnis	937.000.000 $
Nicht operative Posten und Steuern	-246.000.000 $
Nettogewinn	691.000.000 $

BilanzübersichtWie die ausgewiesenen Vermögenswerte im gewählten Zeitraum gehalten und finanziert werden.

StockMarketAgent.AI

Daten zur Bilanzaufgliederung
Gesamtvermögen	15.467.000.000 $
Liquide Mittel	2.312.000.000 $
Umlaufvermögen	6.768.000.000 $
Gesamtverbindlichkeiten	12.136.000.000 $
Kurzfristige Verbindlichkeiten	2.235.000.000 $
Eigenkapital	3.331.000.000 $

Cashflow-ÜberleitungWie der operative Cashflow in FY2025 zum freien Cashflow wurde.

StockMarketAgent.AI

Überleitung des operativen Cashflows

Nettogewinn2,7 Mrd. $Abschreibungen+487 Mio. $Aktienbasierte Vergütung+83 Mio. $Sonstige operative Anpassungen−339 Mio. $Operativer Cashflow2,9 Mrd. $

Überleitung vom Anfangs- zum Endbestand

Anfangsbestand Zahlungsmittel2 Mrd. $Operativer Cashflow+2,9 Mrd. $Cashflow aus Investitionstätigkeit−748 Mio. $Cashflow aus Finanzierungstätigkeit−1,9 Mrd. $Wechselkurseffekt+39 Mio. $Endbestand Zahlungsmittel2,3 Mrd. $

2,9 Mrd. $ − 621 Mio. $Freier Cashflow 2,3 Mrd. $

Daten der Cashflow-Überleitung
Nettogewinn	2.673.000.000 $
Operativer Mittelzufluss	3.243.000.000 $
Abschreibungen	487.000.000 $
Aktienbasierte Vergütung	83.000.000 $
Operativer Cashflow	2.904.000.000 $
Operativer Mittelabfluss	339.000.000 $
Verfügbare Zahlungsmittel	4.930.000.000 $
Anfangsbestand Zahlungsmittel	1.987.000.000 $
Wechselkurseffekt	39.000.000 $
Mittelabfluss aus Investitionen	748.000.000 $
Investitionsausgaben	621.000.000 $
Sonstige Investitionstätigkeiten	127.000.000 $
Mittelabfluss aus Finanzierung	1.870.000.000 $
Netto-Schuldenaufnahme	2.498.000.000 $
Aktienrückkäufe	3.235.000.000 $
Gezahlte Dividenden	889.000.000 $
Sonstige Finanzierungstätigkeiten	244.000.000 $
Endbestand Zahlungsmittel	2.312.000.000 $
Cashflow aus Investitionstätigkeit	-748.000.000 $
Cashflow aus Finanzierungstätigkeit	-1.870.000.000 $

Umsatz und ErgebnisWie sich die Unternehmensgröße in ausgewiesenen Gewinn übersetzt.

Liquidität und SchuldenVerfügbare Liquidität im Verhältnis zur Gesamtverschuldung.

Cashflow-EntwicklungOperativer Cashflow im Vergleich zum freien Cashflow.

ProfitabilitätEntwicklung von Brutto-, Betriebs- und Nettomarge.

Punktbezogene Finanzdaten der Analyse vom 2026-10-22.

Finanzhistorische Daten
Periode	Umsatz	EBITDA	Nettogewinn	Operativer Cashflow	Freier Cashflow	Investitionsausgaben	Abschreibungen	Aktienbasierte Vergütung	Aktienrückkäufe	Gezahlte Dividenden	Netto-Schuldenaufnahme	Cashflow aus Investitionstätigkeit	Cashflow aus Finanzierungstätigkeit	Anfangsbestand Zahlungsmittel	Endbestand Zahlungsmittel	Liquidität und Anlagen	Gesamtverschuldung	Operative Marge	ROIC	WACC	ROIC−WACC-Spanne
2016-12-31	4,9 Mrd. $	1,6 Mrd. $	821 Mio. $	713 Mio. $	497 Mio. $	216 Mio. $	240 Mio. $	37 Mio. $	300 Mio. $	188 Mio. $	—	-214 Mio. $	-903 Mio. $	—	727 Mio. $	727 Mio. $	4,5 Mrd. $	28,7 %	—	5,5 %	—
2017-12-31	5,3 Mrd. $	1,9 Mrd. $	864 Mio. $	1,3 Mrd. $	1,1 Mrd. $	224 Mio. $	242 Mio. $	44 Mio. $	500 Mio. $	206 Mio. $	—	-270 Mio. $	-251 Mio. $	727 Mio. $	1,6 Mrd. $	1,6 Mrd. $	5 Mrd. $	32,5 %	—	5,4 %	—
2018-12-31	5,8 Mrd. $	2,2 Mrd. $	1,4 Mrd. $	1,8 Mrd. $	1,5 Mrd. $	338 Mio. $	308 Mio. $	53 Mio. $	698 Mio. $	243 Mio. $	—	-2,3 Mrd. $	533 Mio. $	1,6 Mrd. $	1,6 Mrd. $	1,7 Mrd. $	6,5 Mrd. $	32,3 %	—	5,7 %	—
2019-12-31	6,3 Mrd. $	2,5 Mrd. $	1,5 Mrd. $	1,8 Mrd. $	1,3 Mrd. $	460 Mio. $	412 Mio. $	67 Mio. $	626 Mio. $	314 Mio. $	—	-504 Mio. $	-951 Mio. $	1,6 Mrd. $	1,9 Mrd. $	1,9 Mrd. $	6,6 Mrd. $	32,2 %	—	5,1 %	—
2020-12-31	6,7 Mrd. $	2,7 Mrd. $	1,6 Mrd. $	2,1 Mrd. $	1,7 Mrd. $	453 Mio. $	441 Mio. $	59 Mio. $	250 Mio. $	380 Mio. $	—	-572 Mio. $	123 Mio. $	1,9 Mrd. $	3,6 Mrd. $	3,6 Mrd. $	7,4 Mrd. $	34,0 %	—	4,0 %	—
2021-12-31	7,8 Mrd. $	3,2 Mrd. $	2 Mrd. $	2,2 Mrd. $	1,7 Mrd. $	477 Mio. $	448 Mio. $	58 Mio. $	743 Mio. $	474 Mio. $	—	-458 Mio. $	-1,9 Mrd. $	3,6 Mrd. $	3,5 Mrd. $	3,5 Mrd. $	6,7 Mrd. $	36,0 %	—	4,8 %	—
2022-12-31	8,1 Mrd. $	3,4 Mrd. $	2,1 Mrd. $	1,9 Mrd. $	1,3 Mrd. $	586 Mio. $	465 Mio. $	62 Mio. $	1,6 Mrd. $	611 Mio. $	1,4 Mrd. $	-883 Mio. $	-904 Mio. $	3,5 Mrd. $	3,6 Mrd. $	3,6 Mrd. $	8,1 Mrd. $	36,2 %	—	7,3 %	—
2023-12-31	8,5 Mrd. $	3,7 Mrd. $	2,3 Mrd. $	2,4 Mrd. $	1,6 Mrd. $	732 Mio. $	491 Mio. $	60 Mio. $	1,1 Mrd. $	692 Mio. $	-1,3 Mrd. $	-777 Mio. $	-3,1 Mrd. $	3,6 Mrd. $	2 Mrd. $	2 Mrd. $	6,8 Mrd. $	35,9 %	—	7,5 %	—
2024-12-31	9,3 Mrd. $	3,9 Mrd. $	2,5 Mrd. $	3 Mrd. $	2,3 Mrd. $	655 Mio. $	497 Mio. $	74 Mio. $	1,9 Mrd. $	786 Mio. $	-3 Mio. $	-315 Mio. $	-2,7 Mrd. $	2 Mrd. $	2 Mrd. $	2 Mrd. $	6,7 Mrd. $	36,6 %	—	8,0 %	—
2025-12-31	9,5 Mrd. $	4,1 Mrd. $	2,7 Mrd. $	2,9 Mrd. $	2,3 Mrd. $	621 Mio. $	487 Mio. $	83 Mio. $	3,2 Mrd. $	889 Mio. $	2,5 Mrd. $	-748 Mio. $	-1,9 Mrd. $	2 Mrd. $	2,3 Mrd. $	2,3 Mrd. $	9,5 Mrd. $	38,0 %	—	7,4 %	—

§9 Bewertungsvergleich mit Vergleichsunternehmen

Zoetis Inc.ZTS

Kurs / fairer Wert

Fairer Wert95,48 $Report-date price79,62 $

Bewertungsdatum22. Okt. 2026

Wirtschaftlicher BurggrabenNarrow

Investment-Scorecard67 / 100

DexCom, Inc.DXCM

Kurs / fairer Wert

Fairer Wert58,97 $Report-date price85,36 $

Bewertungsdatum04. Okt. 2026

Wirtschaftlicher BurggrabenWide

Investment-Scorecard67 / 100

GE HealthCare Technologies Inc.GEHC

Kurs / fairer Wert

Fairer Wert68,29 $Report-date price64,29 $

Bewertungsdatum05. Okt. 2026

Wirtschaftlicher BurggrabenNarrow

Investment-Scorecard62 / 100

Zoetis Inc.ZTS

Kurs / fairer Wert

Fairer Wert95,48 $Report-date price79,62 $

Bewertungsdatum22. Okt. 2026

Wirtschaftlicher BurggrabenNarrow

Investment-Scorecard67 / 100

Vergleichsmultiplikatoren und Rentabilität
Ticker	Name	Marktkap.	P/E	P/S	EV/EBITDA	ROE

Zoetis Inc. (ZTS) trades at 12.0x forward earnings against a peer median of 16.6x. Its EV/EBITDA of 10.0x compares with a peer median of 14.6x. The comparison uses 4 peers: DexCom Inc., GE HealthCare Technologies Inc., ResMed Inc. and Biogen Inc., as of 2026-10-21.

§10 Branche & ZyklusEN

Zyklusphase

Expansion

Industry capex-to-revenue benchmark is 1.1% and industry capex-to-depreciation stands at 0.8x. Zoetis maintains higher capital intensity to support proprietary biologics, investing $621M in capex (6.6% of revenue) in FY2025.⁷

Bullenzyklus

The long-term industry expansion is propelled by pet humanization, increasing medicalization rates in emerging markets, preventative veterinary care, and rising global animal protein demand requiring livestock disease prevention.

Bärenzyklus

Downside industry conditions stem from pet owner price sensitivity, cumulative veterinary inflation over recent years, and discretionary visit deferrals that pressure volume across companion animal clinics.

Säkulare Trends
Trend	Auswirkung	Hinweis
Pet Humanization and Premium Veterinary Care	positive	Pet owners increasingly treat pets as family members, prioritizing advanced therapeutics, diagnostics, and monoclonal antibodies regardless of broader economic fluctuations.
Global Protein Demand and Food Security	positive	Rising middle-class populations in emerging markets drive meat and dairy consumption, increasing demand for herd health biosecurity, vaccines, and productivity enhancers.
Cyclical Pet Owner Price Sensitivity and Visit Moderation

Positionierung

Zoetis holds the #1 market share globally in animal health, with leading positions across major companion animal categories (parasiticides, dermatology, pain) and livestock species (cattle, poultry, swine). Its balanced revenue split between the U.S. ($5,097M) and International ($4,254M) insulates the business against localized market downturns.⁸

§11 PositionsmanagementEN

Positionsgröße

4-6%

High conviction is supported by Zoetis' Narrow economic moat, dominant global distribution scale, 85%+ FCF conversion, and a cyclically low valuation of 11.99x forward P/E.³

Risiko

Risk management centers on monitoring competitive prescription dynamics in canine dermatology and tracking veterinary clinic visit indicators. Exposure is capped strictly within recommended allocation limits, with downside protection provided by livestock diversification and recurring parasiticide volume.

Einstiegstranchen
Niveau	Aktion	Warum
$79.62	Initiate primary position tranche	Establishes exposure at a 16.6% discount to Fair value of $95.48.
Below $79.62	Deploy secondary accumulation tranche

Ausstiegstranchen
Niveau	Aktion
$95.50 (at Fair value)	Trim initial position tranche
$115.00 (approaching upper fair value band)	Trim secondary position tranche

Vierteljährliche Checkpoints
Kennzahl	Schwellenwert	Aktion
U.S. Companion Animal Revenue Decline	Organic revenue contraction worsening significantly beyond full-year guidance ranges in Q3 or Q4 of FY2026	Re-assess gross-to-net discount trajectory and reduce conviction rating.

ZTS	Zoetis Inc.	$32.9B	12.0x	3.5x	10.0x	64.9%	—
DXCM	DexCom Inc.	$32.4B	27.5x	6.5x	22.7x	38.5%	24.3%
GEHC	GE HealthCare Technologies Inc.	$31.9B	13.0x	1.5x	11.3x	19.4%	15.0%
RMD	ResMed Inc.	$34.5B	18.5x	6.1x	16.6x	24.3%	30.9%
BIIB	Biogen Inc.	$35.6B	14.6x	3.6x	12.7x	4.6%	25.1%

Is Zoetis Inc. overvalued?

What is ZTS's fair value?

Should I buy ZTS now?

What are the biggest risks for ZTS?

What is ZTS's rating?

What archetype is ZTS?

Zoetis Inc.

Names readers of ZTS also follow

Unternehmensüberblick

U.S. Companion Animal Organic Revenue Growth

Narrow

Sources of advantage

Lenses that set Fair value

Multi-stage Moat Fade

U.S. Companion Animal Organic Revenue Trend

Dermatology Volume Share and Net Realized Pricing

Sources

Corporate Operating EBIT Margin

Full-Year Adjusted Diluted EPS

International Companion Animal Revenue Growth

Free Cash Flow Conversion of Net Income

Forward Earnings

Cash flow DCF

Owner Earnings

Dividend Discount Model

Checks and reference points

Reverse DCF

PEG-adjusted Peer

International Companion Animal Growth Momentum

Livestock Segment Performance and Outbreak Demand

Share Repurchase Execution and Cash Return Pace